OPBP-1

OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research[1].

C64H92N20O19S

1477.6

O=C(N[C@H](CCC(N)=O)C(N[C@H](CO)C(N[C@H](CCC(O)=O)C(N[C@H](CC1=CNC=N1)C(N[C@H](CC2=CNC=N2)C(N[C@H](CCSC)C(N[C@H](CCCNC(N)=N)C(N[C@H](C(C)C)C(N[C@H](CC3=CC=C(C=C3)O)C(N[C@H](CO)C(N[C@H](CC4=CC=CC=C4)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN

PD-1/PD-L1

99.88

H2O : 5 mg/mL (ultrasonic)

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Blue Ice